InMed is a pre-revenue drug development company focused on cannabinoid-based small molecule therapies. InMed develops proprietary CB1 and CB2 receptor ligands that interact with the endocannabinoid system to produce neuroprotective and anti-inflammatory effects. The company's pipeline includes three primary drug candidates. Its lead candidate, INM-901, is a preclinical small molecule for Alzheimer's disease designed to treat neuroinflammation and synaptic dysfunction. Its second candidate, INM-089, is an intravitreal small molecule in preclinical development to protect retinal cells and reduce drusen deposits in dry age-related macular degeneration. Its third candidate, INM-755, is a topical cannabinol cream that has completed Phase 2 trials for epidermolysis bullosa, a rare blistering skin disease. InMed's business model relies on funding preclinical and clinical R&D to advance drug candidates toward regulatory approval or strategic partnerships. InMed plans to monetize its assets through out-licensing, co-development agreements with larger pharmaceutical companies, or strategic transactions, with further pipeline development contingent on securing additional financing.